

PIXYL

One line pitch:

Pixyl automatically extracts biomarkers from neuro-images for improved insight and decision-making in clinical trials and clinical routine practice

Market Analysis:

Neuroimaging biomarkers are more and more used as outcome of clinical trials to assess treatment study efficiency, and in clinical routine practice to establish a clinical diagnosis, prognosis, and assess the evolution of a particular disease. In privately funded clinical trials, contract research organizations, biotechs and biopharmas are Pixyl customers. They are neurologists and neuro-radiologists in publicly funded trials and in clinical routine. Market size for: - clinical trials (privately and publicly funded): 104M€ in 2021 - clinical routine: 1.7B€ in 2021

Value proposition:

Pixyl offers an automatic, objective and reliable biomarkers extraction solution. Automatic solution allows clinical trials actors to focus on other aspects of the trial, without the burden to find and train expert raters. In clinical routine, neurologists and neuroradiologists have more time to focus on their patient. Objective solution allows clinical trial actors to be more confident into their results, making it easier to decide to pursue to the next trial phase. In clinical routine, practitioners have a better insight in patient disease status. Reliable solution allows consistency in different analysis timepoints to assess treatment efficiency in clinical trial or in clinical routine.

Business Model:

For clinical trials market, Pixyl will provide project-based licenses restricted to one clinical trial. Pixyl solution will either be accessible through Contract Research Organization specialized in imaging, or directly through its web service. For clinical routine market, Pixyl will provide access to its web service through a user annual subscription.

IP and Regulatory situation:

The Pixyl technology is subject to an exclusive license, with option to buy, between Pixyl and INRIA. The technology has been entirely developed by members of the Pixyl team, and is not distributed or shared. Moreover, the Pixyl source-code is subject to an Agence pour la Protection des Programmes (A.P.P.) deposit. Pixyl has not pursued a patent strategy in order to retain control of the technology behind the product.



COMPANY PROFILE

- **Website:**
www.pixylmedical.com
- **Field:**
- **Contact:**
LANGENIEUX Alexandre
Alexandre.Langenieux@pixyl.io
- **Location:**
INRIA, 655, Avenue de l'Europe
38330 Montbonnot Saint MARTIN
France
- **Founded in:** //03/2015
- **Employees:** 5
- **Financial information (€):**
 - **Company stage:**
Scalability phase
 - **Capital raised to date:**
151 000
 - **Monthly burn rate:**
15 000
 - **Capital seeking and date:**
600 000, Q4 2016
- **Investors:**
IT-Translation, Founders,
Individuals